TriSalus Life Sciences, Inc. (TLSIW) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
6272 WEST 91ST AVENUE WESTMINSTER, CO 80031 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 3841 - Surgical and Medical Instruments and Apparatus (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 8,525 | 11,777 | 154 | 201 | 1,335 | |||
| Cash and cash equivalent | 8,525 | 11,777 | 154 | 201 | 1,335 | |||
| Receivables | 5,087 | 3,554 | ||||||
| Inventory, net of allowances, customer advances and progress billings | 4,048 | 2,545 | ||||||
| Inventory | 4,048 | 2,545 | ||||||
| Prepaid expense | 3,009 | 2,986 | 206 | 325 | 673 | |||
| Total current assets: | 20,669 | 20,862 | 360 | 526 | 2,008 | |||
| Noncurrent Assets | ||||||||
| Finance lease, right-of-use asset, after accumulated amortization | 128 | 233 | ||||||
| Operating lease, right-of-use asset | 1,210 | 1,179 | ||||||
| Intangible assets, net (including goodwill) | 1,127 | |||||||
| Intangible assets, net (excluding goodwill) | 1,127 | |||||||
| Asset, held-in-trust | 19,828 | 250,007 | 250,003 | |||||
| Restricted cash and investments | 350 | 350 | ||||||
| Other noncurrent assets | 423 | 466 | ||||||
| Other undisclosed noncurrent assets | 1,191 | 1,508 | ||||||
| Total noncurrent assets: | 3,302 | 4,863 | 19,828 | 250,007 | 250,003 | |||
| TOTAL ASSETS: | 23,971 | 25,725 | 20,188 | 250,533 | 252,011 | |||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities, including: | 9,629 | 13,947 | 28 | 1,058 | 103 | |||
| Accounts payable | 2,274 | 3,391 | ||||||
| Accrued liabilities | 7,355 | 10,556 | 28 | 103 | ||||
| Other undisclosed accounts payable and accrued liabilities | 1,058 | |||||||
| Debt | 78 | 76 | ||||||
| Other liabilities | 383 | 389 | ||||||
| Due to related parties | ✕ | ✕ | ✕ | 992 | ||||
| Other undisclosed current liabilities | 138 | 275 | 1,482 | |||||
| Total current liabilities: | 10,228 | 14,687 | 2,502 | 1,058 | 103 | |||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 22,102 | 88 | ||||||
| Long-term debt, excluding current maturities | 22,084 | |||||||
| Finance lease, liability | 18 | 88 | ||||||
| Liabilities, other than long-term debt | 17,028 | 36,888 | ||||||
| Operating lease, liability | 1,311 | 1,156 | ||||||
| Business combination, contingent consideration, liability | 7,401 | 18,632 | ||||||
| Derivative instruments and hedges, liabilities | 8,316 | 17,100 | ||||||
| Other undisclosed noncurrent liabilities | 507 | 11,152 | ||||||
| Total noncurrent liabilities: | 39,637 | 36,976 | 11,152 | |||||
| Other undisclosed liabilities | 16,193 | 23,393 | ||||||
| Total liabilities: | 49,865 | 51,663 | 13,654 | 17,250 | 23,496 | |||
| Temporary equity, including noncontrolling interest | 250,000 | 250,000 | ||||||
| Equity | ||||||||
| Equity, attributable to parent, including: | (25,894) | (25,938) | (13,267) | (16,717) | (21,484) | |||
| Common stock | 3 | 2 | ||||||
| Additional paid in capital | 253,652 | 222,437 | ||||||
| Accumulated deficit | (279,549) | (248,377) | (13,267) | (16,718) | (21,485) | |||
| Other undisclosed equity, attributable to parent | 1 | 1 | 1 | |||||
| Other undisclosed equity | 19,800 | |||||||
| Total equity: | (25,894) | (25,938) | 6,533 | (16,717) | (21,484) | |||
| TOTAL LIABILITIES AND EQUITY: | 23,971 | 25,725 | 20,188 | 250,533 | 252,011 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|---|
| Revenues | 29,431 | 18,511 | |||||
| Cost of revenue (Cost of Product and Service Sold) | (4,103) | (2,605) | |||||
| Gross profit: | 25,328 | 15,906 | |||||
| Operating expenses | (61,493) | (70,056) | (2,746) | (3,041) | |||
| Operating loss: | (36,165) | (54,150) | (2,746) | (3,041) | |||
| Nonoperating income | 92 | 52 | 8,856 | 7,808 | |||
| Investment income, nonoperating | 404 | 431 | 3,019 | 64 | |||
| Other nonoperating expense | (312) | (379) | |||||
| Interest and debt expense | (3,090) | (16) | |||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (39,163) | (54,114) | 6,110 | 4,767 | |||
| Other undisclosed income (loss) from continuing operations before income taxes | 9,124 | (4,915) | |||||
| Income (loss) from continuing operations before income taxes: | (30,039) | (59,029) | 6,110 | 4,767 | |||
| Income tax expense (benefit) | (6) | (9) | (571) | 625 | |||
| Income (loss) from continuing operations: | (30,045) | (59,038) | 5,539 | 5,392 | |||
| Income before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | 5,392 | ✕ | |
| Other undisclosed net loss | (625) | ||||||
| Net income (loss) attributable to parent: | (30,045) | (59,038) | 5,539 | 4,767 | |||
| Preferred stock dividends and other adjustments | (3,188) | (4,239) | (2,171) | ||||
| Net income (loss) available to common stockholders, diluted: | (33,233) | (63,277) | 3,368 | 4,767 | |||
Comprehensive Income ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|---|---|---|
| Net income (loss): | (30,045) | (59,038) | 5,539 | 4,767 | |||
| Comprehensive income (loss), net of tax, attributable to parent: | (30,045) | (59,038) | 5,539 | 4,767 | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.